? Proteomics (PROT) Shared Resource The UNC Proteomics (PROT) Shared Resource (SR) provides state-of-the-art mass spectrometry-based qualitative and quantitative protein analyses for LCCC members. The PROT SR offers a variety of services to cancer researchers including: guidance in experimental design; protein and peptide identification; relative and absolute protein quantitation; analysis of protein modifications; activity-based proteomics; instrument training; and proteomic informatics. In addition to these basic proteomic services there are four cancer proteomic research themes, each involving active collaborations with LCCC investigators, which have been developed since the last renewal. These themes provide state-of-the art proteomic research technologies to members of the Cancer Center and include: i) chemical proteomics methods to interrogate the dynamic activation state of the cancer kinome; ii) quantifying both the proteome and phosphoproteome of patient tumors as part of the NCI CPTAC initiative; iii) mass spectrometry and computational methods for defining protein-protein interaction networks in cancer, including quantitative measurement of network dynamics; and iv) absolute quantification of proteins in complex protein mixtures by selective reaction monitoring (SRMs). The PROT SR is led by Lee Graves (MT), Professor of Pharmacology and director, and David Smalley, Facility Director. Three additional faculty are directly involved with the efforts of the PROT SR: Gary Johnson (MT), Kenan Distinguished Professor and Chair of the Department of Pharmacology and co-director of the Molecular Therapeutics Program, Ben Major (CCB), Associate Professor of Cell Biology & Physiology, and Xian Chen (IM), Professor of Biochemistry & Biophysics and technology director of the PROT SR. Together they provide strong synergistic leadership in mass spectrometry based proteomics with a proven record of productive collaboration with investigators in the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-44
Application #
9834850
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Zuze, Takondwa; Painschab, Matthew S; Seguin, Ryan et al. (2018) Plasmablastic lymphoma in Malawi. Infect Agent Cancer 13:22
Wang, Jeremy R; Holt, James; McMillan, Leonard et al. (2018) FMLRC: Hybrid long read error correction using an FM-index. BMC Bioinformatics 19:50
Lee, Janie M; Abraham, Linn; Lam, Diana L et al. (2018) Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography. J Clin Oncol 36:2070-2077
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Shao, Wenwei; Chen, Xiaojing; Samulski, Richard J et al. (2018) Inhibition of antigen presentation during AAV gene therapy using virus peptides. Hum Mol Genet 27:601-613
Gao, Yanzhe; Kardos, Jordan; Yang, Yang et al. (2018) The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Sci Rep 8:15304
Schaefer, Kristina N; Bonello, Teresa T; Zhang, Shiping et al. (2018) Supramolecular assembly of the beta-catenin destruction complex and the effect of Wnt signaling on its localization, molecular size, and activity in vivo. PLoS Genet 14:e1007339
Bonacci, Thomas; Suzuki, Aussie; Grant, Gavin D et al. (2018) Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/C substrates. EMBO J 37:
Zhang, Zhi-Min; Lu, Rui; Wang, Pengcheng et al. (2018) Structural basis for DNMT3A-mediated de novo DNA methylation. Nature 554:387-391
Desai, Neelam V; Torous, Vanda; Parker, Joel et al. (2018) Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay. Breast Cancer Res 20:75

Showing the most recent 10 out of 1525 publications